Hyperuricaemia and gout: Clinical guideline 2003

South African Medical Journal

Volumn 93, Issue 12 II, 2003, Pages 961-970

  Meyers, O L ^a   Cassim, B ^a   Mody, G M ^a  

^a South African Medical Association   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ALLOPURINOL PLUS BENZBROMARONE; ANTICOAGULANT AGENT; AZATHIOPRINE; BENZBROMARONE; BETAMETHASONE; COLCHICINE; CORTICOSTEROID; CORTICOTROPIN; DIURETIC AGENT; MERCAPTOPURINE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; OXIPURINOL; PREDNISONE; PROBENECID; SALICYLIC ACID DERIVATIVE; SULFINPYRAZONE; URIC ACID; URICOSURIC AGENT;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL FEATURE; DIAGNOSTIC TEST; DIARRHEA; DIET THERAPY; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE ASSOCIATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; EPIDEMIOLOGICAL DATA; GOUT; HUMAN; HYPERURICEMIA; KIDNEY DISEASE; KIDNEY DYSFUNCTION; LIVER TOXICITY; LONG TERM CARE; NAUSEA AND VOMITING; NEPHROLITHIASIS; PATHOPHYSIOLOGY; PATIENT EDUCATION; PATIENT REFERRAL; PRACTICE GUIDELINE; TOXIC EPIDERMAL NECROLYSIS; TREATMENT PLANNING; URIC ACID BLOOD LEVEL;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHILD; COLCHICINE; FEMALE; GOUT; GOUT SUPPRESSANTS; HUMANS; HYPERURICEMIA; MALE; MIDDLE AGED; PRACTICE GUIDELINES; URIC ACID;

EID: 0347269098     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Wortmann RL. Gout and other disorders of purine metabolism. In: Fauci AS, ed. Harrison's Principals of Internal Medicine. 14th ed. New York: MacGraw-Hill, 1998: 2158-2165.
2. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Ageing Study. Am J Med 1987; 82: 421-426.
3. Wyngaarden JB, Holmes EW. Clinical gout and the pathogenesis of hyperuricaemia. In: McCarthy DJ, ed. Arthritis and Allied Conditions, 9th ed. Philadelphia: Lea & Febiger, 1979.
4. Scott JT, Higgens CS. Diuretic-induced gout: a multifactorial condition. Ann Rheum Dis 1992; 51: 259-261.
5. Mikkelsen WM, Dodge HJ, Valkenburg H, Himes S. The distribution of serum uric acid values in a population unselected as to gout or hyperuricaemia. Am J Med 1965; 39: 242-251.
6. Roubenoff R. Gout and hyperuricemia. Rheum Dis Clin North Am 1990; 16: 539-550.
7. Currie WJC. Prevalence and incidence of gout in Great Britain. Ann Rheum Dis 1979; 38: 101-106.
8. Beighton P, Solomon L, Soskolne CL, Sweet B, Robin G. Serum uric acid concentrations in an urbanized South African Negro population. Ann Rheum Dis 1974; 33: 442-445.
9. Beighton P, Solomon L, Soskolne CL, Sweet B. Serum uric acid concentrations in a rural Tswana community in Southern Africa. Ann Rheum Dis 1973; 32: 346-350.
10. Cassim B, Mody GM, Deenadayalu VK, Hammond MG. Gout in black Africans: A clinical and genetic study. Ann Rheum Dis 1994; 53: 759-762.
11. Tikly M, Bellingan A, Lincoln D, Russell A. Risk factors for gout: a hospital-based study in urban black South Africans. Revue Du Rhumatisme, English edition. 1998; 65: 225-231.
12. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu T-F. Preliminary criteria for the classification of acute arthritis of primary gout. Arthritis Rheum 1977; 20: 895-900.
13. Harris MD, Siegel LB, Alloway JA. Gout and hypertension. Am Fam Physician 1999; 15: 925-934.
14. Macfarlane DG, Dieppe PA. Diuretic induced gout in elderly women. Br J Rheum 1985; 24: 155-157.
15. Meyers OL, Monteguado FSE. A comparison of gout in men and women: a 10 year experience. S Afr Med J 1986; 70: 721-723.
16. Lawry II GV, Fan PT, Bluestone MB. Polyarticular versus monoarticular gout: A prospective, comparative analysis of clinical features. Medicine 1988; 67: 335-343.
17. Hadler N, Franck WA, Bress NM, Robinson DR. Acute polyarticular gout. Am J Med 1974; 56: 715-719.
18. Rogachefsky RA, Carneiro, R, Altman RD et al. Gout preventing as infectious arthritis: two case reports. J Bone Joint Surg Am 1994; 76: 269-273.
19. Arnold MH, Preston SJ, Buchanan WW. Comparison of the natural history of untreated acute gouty arthritis vs acute gouty arthritis treated with non-steroidal anti-inflammatory drugs. Br J Clin Pharmacol 1988; 26: 4889.
20. Emmerson BT. The management of gout. N Engl J Med 1996; 334: 445-455.
21. Lin HY, Rocher LL, McQuillan MA, Schmaltz S, Palella TD, Fox IH. Cyclosporine-induced hyperuricemia and gout. N Engl J Med 1989; 321: 287-292.
22. Fessel WJ. Renal outcomes of gout and hyperuricemia. Am J Med 1979; 67: 74-82.
23. Andreoli SP, Clark JH, McGuire WA, Bergstein JM. Purine excretion during tumor lysis in children with acute lymphocytic leukaemia receiving allopurinol: relationship to acute renal failure. J Pediatr 1986; 190: 292-298.
24. Facchini F, Chen YD, Hollenbeck CB, Reaven GM. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 1991; 266: 3008-3011.
25. Emmerson B. Hyperlipidaemia in hyperuricaemia and gout. Lancet 1998; 57: 509-510.
26. Cohen MG, Emmerson BT. Gout. In: Klippel JH, Dieppe PA, eds. Rheumatology. 1st ed. St Louis: Mosby, 1994: 12.11-12.16.
27. Berkowitz D. Gout, hyperlipidaemia and diabetes: interrelationships. JAMA 1966; 197: 77-80.
28. Schlesinger N, Baker DG, Schumaker HR jun. How well have diagnostic tests and therapies for gout been evaluated? Curr Opin Rheumatol 1999; 11: 441-445.
29. McDonald E, Marino C. Stopping progression to tophaceous gout: when and how to use urate loweing therapy. Postgrad Med 1998; 104: 117-127.
30. Buckley TJ. Radiologic features of gout. Am Fam Physician 1996; 54: 1232-1238.
31. Star VL, Hochberg MC. Prevention and management of gout. Drugs 1993; 15: 212-222.
32. Allison MC, Howatson AG, Torrance CJ, Lee FD, Russell RI. Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. N Engl J Med. 1992; 327: 749-754.
33. Dieppe PA. Investigation and management of gout in the young and the elderly. Ann Rheum Dis 1991; 50: 263-266.
34. Fam AG. Strategies and controversies in the treatment of gout and hypecuricaemia. Ballieres Clin Rheumatol 1990; 4: 177-192.
35. Evans TI, Wheeler MT, Small RE, Breitbach SA, Saunders KM, Roberts WN. A comprehensive investigation of inpatient colchicine shows more education is needed. J Rheumatol 1996; 23: 143-148.
36. Groff GD, Franck WA, Raddatz, DA. Systemic steroid therapy for acute gout: a clinical trial and review of the literature. Sem Arthritis Rheum 1990; 19: 329-336.
37. Axelrod D, Preston S. Comparison of parenteral adrenocorticotropic hormone with oral indomethacin in the treatment of acute gout. Arthritis Rheum 1988; 31: 803-805.
38. Gray RG, Tenenbaum J, Gottlieb NL. Local corticosteroid injections treatment in rheumatic disorders. Semin Arthritis Rheum 1981; 10: 231-254.
39. Fox IH. Metabolic basis for disorders of purine nucleotide degradation. Metabolism 1981; 30: 616-634.
40. Gibson T, Rodgers AV, Simmonds HA, Toseland P. Beer drinking and its effect on uric acid. Br J Rheumatol 1984; 23: 203-209.
41. Ben-Chetrit E, Levy M. Colchicine 1998 update. Semin Arthritis Rheum 1998; 28: 48-59.
42. Wallace SL, Singer JZ, Duncan GJ, Wigley FM, Kuncl RW. Renal function predicts colchicine toxicity: guidelines for the prophylactic use of colchicine in gout. J Rheumatol 1991; 18(2): 264-269.
43. Fam AG, Lewtas J, Stein J, Paton TW. Desensitization to allopurinol in patients with gout and cutaneous reactions. Am J Med 1992; 93(3): 299-302.
44. Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, Herrero-Beites A, Garcia-Erauskin G, Ruiz-Lucea E. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 1998; 57(9): 545-549.
45. Emmerson BT, Gordon RB, Cross M, Thomson DB. Plasma oxipurinol concentration during allopurinol therapy. Br J Rheumatol 1987; 26(6): 445-449.
46. Arellano F, Sacristan JA. Allopurinol hypersensitivity syndrome: a review. Ann Pharmacotherapy 1993; 27(3): 337-343.
47. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984; 76(1): 47-56.
48. Venkat Raman G, Sharman VL, Lee HA. Azathioprine and allopurinol: a potentially dangerous combination. J Intern Med 1990; 228(1): 69-71.
49. Rundles RW. Effects of 6-mercaptopurine therapy in neoplastic diseases. Ann Rheum Dis 1966; 25: 655-656.